Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer

Fig. 2

STING agonism combined with neutralization of IL-10 and PD-L1 after chemotherapy increases survival. Different combinations of chemotherapy and immunotherapy were tested in vivo for synergy. Kaplan-Meier curves are shown for mice treated with chemotherapy and (a) anti-IL-10, GR-MD-02, and anti-4-1BB, b 2′3’-cGAMP, GR-MD-02, and anti-4-1BB (c) gemcitabine, 2′3’-cGAMP, and anti-PD-L1, d anti-IL-10, 2′3’-cGAMP, and anti-4-1BB, or (e) anti-IL-10, 2′3’-cGAMP, and anti-PD-L1. a-e All combination treatments were compared to chemotherapy and isotype control for immunotherapy (Chemo) 8 days after inoculation of ID8-Vegf-Defb29 cells. The number of mice per group (n) and median survival (ms) are listed. The experiment was performed with biological replicates twice. Statistics were calculated relative to the group treated with chemotherapy only using the Log-rank (Mantel-Cox) test. ** p ≤ 0.01, **** p ≤ 0.0001

Back to article page